HIATT WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med, 2001, 344: 1608-1621.
Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost effectiveness analyses. J Cardiovasc Pharmacol., 1995, 25(2): 44-50.
Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 1996, 25(6): 1172-81.
Meijer WT, Cost B, Bernsen RM, Hoes AW, Incidence and management of intermittent claudication in primary care in The Netherlands. Scandinavian Journal of Primary Health Care, 2002, 20(1): 33-4.
Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Seminars in Vascular Surgery, 1999, 12(2): 123-37.
Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med, 1979, 300: 713-7,
Trental (pentoxifylline) product information. Kansas City, MO: Hoechst Marion Roussel.
Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation, 1998, 98: 678-86.
Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs, 1987, 34: 50-97.
Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol, 1994, 30: 603-21.
Yoshitomi Y, Kojima S, Sugi T et al. Antiplatelet treatment with cilostazol after stent implantation. Heart, 1999, 80: 393-6.
Girolami A, Buller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a metaanalysis. Arch Intern Med, 1999, 159: 337-45.
Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: a meta-analysis of randomized controlled trials. Can Med Assoc J, 1996, 155: 1053-9.
Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology, 1994, 45: 339-45.
Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med, 1990, 113: 135-46.
Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology, 1992, 43: 121-5.
Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J, 1982, 104: 66-72.
Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation, 1989, 80: 1549-56.
Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology, 1984, 35: 396-406.
Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent clau-dication. Angiology, 1983, 34: 40-5.
Green RM, McNamara J. The effects of pentoxi-fylline on patients with intermittent claudication. J Vase Surg, 1988, 7: 356-62.
Покровский А.В., Калинин А.А., Чупин А.В., Замский К.С., Колосов Р.В., Маркосян АА. Вазонит ретард в лечении больных с перемежающейся хромотой при облитерирующих заболеваниях артерий нижних конечностей. Ангиология и сосудистая хирургия, 2003, 9(2): 19.
Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews, 2012, Issue 1. Art. No.: CD005262. DOI: 10.1002/14651858.CD005262. pub2..
DOI: 10.1002/14651858.CD005262. pub2
Национальные рекомендации по ведению пациентов с патологией артерий нижних конечностей: ангиология и сосудистая хирургия. Приложение. 2013. 19(2): 1-67.